Since heterozygosity at classical HLA-I genes or high HED levels of HLA-B alleles had been found to be associated with improved survival in cancer patients treated with ICIs (45, 46), we assumed that individuals who are heterozygous for HLA or with high HED levels also have a higher incidence of irAEs. This evidence concerns the gene HLA-B and cancer.